3results about How to "Increased cleavage" patented technology

Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

A novel pharmaceutical composition for treating ALS is provided comprising as the active ingredient an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4. A pharmaceutical composition for treating ALS comprising an anti-EphA4 antibody is provided, wherein the anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 44, a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 27, and a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 28, and a light chain comprising a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 29, a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 30, and a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 31.

Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.